Facetten
Zugriff
Einrichtung
Medientyp
- Text 52
Karte
Erscheinungsjahr
Autor/in
- Weisel, Katja
- Moreau, Philippe 7
- Bokemeyer, Carsten 6
- Goldschmidt, Hartmut 6
- Cavo, Michele 5
- alle zeigen
Sprache
52 Einträge gefunden
-
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
- Ghandili, Susanne
- Alihodzic, Dzenefa
- Wiessner, Christian
- Bokemeyer, Carsten
- Weisel, Katja
- Leypoldt, Lisa B
-
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
- Weisel, Katja
- Dimopoulos, Meletios A
- San-Miguel, Jesús
- Paner, Agne
- Engelhardt, Monika
- Taylor, Fiona
- Lord-Bessen, Jennifer
-
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
- Weisel, Katja
- Nooka, Ajay K
- Terpos, Evangelos
- Spencer, Andrew
- Goldschmidt, Hartmut
- Dirnberger, Franziska
- DeCosta, Lucy
-
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
- D'Souza, Anita
- Shah, Nina
- Rodriguez, Cesar
- Voorhees, Peter M
- Weisel, Katja
- Bueno, Orlando F
- Pothacamury, Rajvineeth K
-
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
- Hambach, Julia
- Fumey, William
- Stähler, Tobias
- Gebhardt, Anna Josephine
- Adam, Gerhard
- Weisel, Katja
- Koch-Nolte, Friedrich
-
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
- Weisel, Katja
- Krishnan, Amrita
- Schecter, Jordan M
- Vogel, Martin
- Jackson, Carolyn C
- Deraedt, William
- Yeh, Tzu-Min
-
Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
- Krohn, Steffen
- Boje, Ammelie Svea
- Gehlert, Carina Lynn
- Lutz, Sebastian
- Darzentas, Nikos
- Knecht, Henrik
- Herrmann, Dietrich
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- Mateos, Maria-Victoria
- Weisel, Katja
- De Stefano, Valerio
- Goldschmidt, Hartmut
- Delforge, Michel
- Mohty, Mohamad
- Cavo, Michele
-
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
2022 - Forschungsinformationssystem des UKE - frei zugänglich -
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
- Lonial, Sagar
- Popat, Rakesh
- Hulin, Cyrille
- Jagannath, Sundar
- Oriol, Albert
- Richardson, Paul G
- Facon, Thierry
-
Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy
- Weisel, Katja
- Wadlund, Astrid Ottosson
- Gungor, Guntug
- Dergarabetian, Eileen
- Pacheco, Cécile
- Masurkar, Nihar
- Rodriguez-Otero, Paula
-
-
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
- Hillengass, Jens
- Cohen, Adam D
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Raab, Marc-Steffen
-
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
- Pape, Luca Julius
- Hambach, Julia
- Gebhardt, Anna Josephine
- Rissiek, Björn
- Stähler, Tobias
- Tode, Natalie
- Khan, Cerusch
-
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
- Leleu, Xavier
- Martin, Thomas
- Weisel, Katja
- Schjesvold, Fredrik
- Iida, Shinsuke
- Malavasi, Fabio
- Manier, Salomon
-
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
- Landgren, Ola
- Weisel, Katja
- Rosinol, Laura
- Touzeau, Cyrille
- Turgut, Mehmet
- Hajek, Roman
- Mollee, Peter
-
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
- Weisel, Katja
- Martin, Thomas
- Krishnan, Amrita
- Jagannath, Sundar
- Londhe, Anil
- Nair, Sandhya
- Diels, Joris
-
COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
- Modemann, Franziska
- Ghandili, Susanne
- Schmiedel, Stefan
- Weisel, Katja
- Bokemeyer, Carsten
- Fiedler, Walter
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
- Richardson, Paul G
- Schjesvold, Fredrik
- Weisel, Katja
- Moreau, Philippe
- Anderson, Larry D
- White, Darrell
- Rodriguez-Otero, Paula
-
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
- Dimopoulos, Meletios
- Weisel, Katja
- Moreau, Philippe
- Anderson, Larry D
- White, Darrell
- San-Miguel, Jesus
- Sonneveld, Pieter